Prescient Therapeutics Reports Strong Progress in PTX-100 Phase 2a Study and New CMO Appointment
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Prescient Therapeutics anchors biotech penny watchlists as its OmniCAR cell therapy platform draws steady attention,...
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.
PTX-100 targets high-mortality cancers linked to RAS mutations.
Prescient Therapeutics (ASX: PTX) begins Phase 2A trial of PTX-100 for rare lymphoma, drug shows...
Prescient Therapeutics Ltd (ASX: PTX) initiates a Phase 2a clinical trial for PTX-100 in cutaneous...
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a...
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.